Alivexis, Inc.
June 17, 2025
Company Presentation
Immunology
Alivexis, Inc. is a computation-driven drug discovery firm with offices in both Japan and the US. By combining our proprietary cutting-edge computational technology with our deep insights in disease biology and globally networked operations, we are propelling our proprietary portfolio of small molecule R&D programs as well as biopharma collaborations. Alivexis is dedicated to rapidly delivering innovative medicines to individuals and their families suffering from cancer, chronic and acute inflammatory conditions, and rare diseases.
Company HQ City:
Minato-ku
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
2017
Lead Product in Development:
MOD-A: Non-Covalent CatC Inhibitor
CEO
S. Roy Kimura, Ph.D.
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
6
When you expect your next catalyst update?
TBC
What is your next catalyst (value inflection) update?
TBC
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}